Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-65.51%
operating margin TTM
-55.88%
revenue TTM
11.75 Million
revenue per share TTM
2.63$
valuation ratios | |
|---|---|
| pe ratio | -0.50 |
| peg ratio | 0.00 |
| price to book ratio | 2.06 |
| price to sales ratio | 0.33 |
| enterprise value multiple | -1.36 |
| price fair value | 2.06 |
profitability ratios | |
|---|---|
| gross profit margin | 53.01% |
| operating profit margin | -55.88% |
| pretax profit margin | -66.3% |
| net profit margin | -65.51% |
| return on assets | -70.81% |
| return on equity | -388.56% |
| return on capital employed | -83.23% |
liquidity ratios | |
|---|---|
| current ratio | 2.20 |
| quick ratio | 1.25 |
| cash ratio | 0.39 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 186.73 |
| operating cycle | 254.39 |
| days of payables outstanding | 32.78 |
| cash conversion cycle | 221.61 |
| receivables turnover | 5.39 |
| payables turnover | 11.14 |
| inventory turnover | 1.95 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.55 |
| debt equity ratio | 3.22 |
| long term debt to capitalization | 0.72 |
| total debt to capitalization | 0.76 |
| interest coverage | -9.84 |
| cash flow to debt ratio | 0.15 |
cash flow ratios | |
|---|---|
| free cash flow per share | 1.14 |
| cash per share | 1.94 |
| operating cash flow per share | 1.46 |
| free cash flow operating cash flow ratio | 0.78 |
| cash flow coverage ratios | 0.15 |
| short term coverage ratios | 4.25 |
| capital expenditure coverage ratio | 4.62 |
Frequently Asked Questions
When was the last time Harvard Bioscience, Inc. (NASDAQ:HBIO) reported earnings?
Harvard Bioscience, Inc. (HBIO) published its most recent earnings results on 06-11-2025.
What is Harvard Bioscience, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Harvard Bioscience, Inc. (NASDAQ:HBIO)'s trailing twelve months ROE is -388.56%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Harvard Bioscience, Inc. (HBIO) currently has a ROA of -70.81%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did HBIO's net profit margin stand at?
HBIO reported a profit margin of -65.51% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is HBIO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.20 in the most recent quarter. The quick ratio stood at 1.25, with a Debt/Eq ratio of 3.22.